首页> 外文期刊>Therapeutic Drug Monitoring >Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.
【24h】

Nonsteroidal anti-inflammatory drugs may reduce enterohepatic recirculation of mycophenolic acid in patients with childhood-onset systemic lupus erythematosus.

机译:非甾体类抗炎药可能会减少儿童期系统性红斑狼疮患者的霉酚酸肠肝循环。

获取原文
获取原文并翻译 | 示例
       

摘要

BACKGROUND: The large interindividual differences observed in mycophenolic acid (MPA) pharmacokinetics (MPA-PK) are in part attributed to the large variability in enterohepatic recirculation (EHC) of the drug. The main metabolite of MPA, MPA glucuronide is actively secreted into the bile via the multidrug resistance-associated protein 2 (MRP2) transporter. Nonsteroidal anti-inflammatory drugs (NSAIDs) have been shown to inhibit the MRP2 transporter, which can alter EHC and drug exposure. Here, we evaluated the effects of this potential drug-transporter interaction on MPA-PK in a cohort of patients with childhood-onset systemic lupus erythematosus on mycophenolate mofetil therapy. MATERIALS AND METHODS: Full MPA concentration-time profiles and demographics including comedications were available for 19 patients with childhood-onset systemic lupus erythematosus. Concentrations at predose (C(trough)), 9 hour (C), and nadir (C(nadir); defined as the lowest concentration between C(max) and C), and area under the curve (AUC and AUC) were assessed using standard methods (WinNonlin5.1). AUC6-12/AUC and C/C(nadir) ratios were used to evaluate the effects of NSAID treatment on MPA-PK. RESULTS: Eleven out of 19 patients were on NSAID treatment and did not show visual evidence of EHC in their PK profile. In contrast, patients not on NSAID therapy showed evidence of EHC-related MPA concentration increase in the later part of their PK profiles, typically after 6 hours. This phenomenon could be well characterized by the C/C(nadir) ratio, which was significantly lower in the NSAID-treated cohort (P < 0.01). CONCLUSIONS: These preliminary data suggest that the concomitant intake of NSAIDs may lower EHC of MPA possibly through the inhibition of MRP2 transport of MPA-G. Further mechanism-based studies are needed to further elucidate this potential transporter interaction.
机译:背景:在霉酚酸(MPA)药代动力学(MPA-PK)中观察到的个体差异较大,部分归因于该药物在肠肝循环(EHC)中的巨大差异。 MPA的主要代谢产物MPA葡萄糖醛酸苷通过多药耐药相关蛋白2(MRP2)转运蛋白被主动分泌到胆汁中。非甾体类抗炎药(NSAIDs)已显示抑制MRP2转运蛋白,后者可改变EHC和药物暴露。在这里,我们评估了霉菌酸酯治疗儿童期系统性红斑狼疮患者队列中这种潜在的药物-转运蛋白相互作用对MPA-PK的影响。材料与方法:19例儿童期系统性红斑狼疮患者可获得完整的MPA浓度-时间曲线和人口统计数据,包括喜剧药物。评估了服药前(C(谷)),9小时(C)和最低点(C(最低点;定义为C(最大)和C之间的最低浓度))的浓度以及曲线下面积(AUC和AUC)使用标准方法(WinNonlin5.1)。 AUC6-12 / AUC和C / C(最低点)比率用于评估NSAID治疗对MPA-PK的影响。结果:19名患者中有11名接受了NSAID治疗,并且在其PK谱中未显示出EHC的视觉证据。相反,未接受NSAID治疗的患者通常在6小时后,在其PK曲线的后期显示EHC相关MPA浓度增加的证据。这种现象可以通过C / C(最低点)比率很好地表征,在NSAID治疗组中该比率明显更低(P <0.01)。结论:这些初步数据表明,NSAIDs的同时摄入可能通过抑制MPA-G的MRP2转运而降低MPA的EHC。需要进一步的基于机理的研究来进一步阐明这种潜在的转运蛋白相互作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号